Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: A key role for IKs

British Journal of Pharmacology

Volumn 159, Issue 1, 2010, Pages 93-101

  Ducroq, J ^a   Moha Ou Maati, H ^a,b   Guilbot, S ^a   Dilly, S ^a   Laemmel, E ^c   Pons Himbert, C ^d   Faivre, J F ^b   Bois, P ^b   Stucker O ^d   Le Grand, M ^a  

^a ZI de Brenas ^*  (United States)

^b UNIVERSITÉ DE POITIERS   (France)

^c Laboratoire d'Etude de la Microcirculation   (France)

^d CEROM   (France)

Author keywords

Dexrazoxane; Doxorubicin; HERG; IKr; IKs; ICHS7B guideline; Isolated guinea pig heart; KvLQT1 MinK; Moxifloxacin; QT interval

Indexed keywords

DOXORUBICIN; MOXIFLOXACIN; POTASSIUM CHANNEL HERG; RAZOXANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ELECTROCARDIOGRAM; ELECTROPHYSIOLOGY; GUINEA PIG; HEART RATE; HUMAN; HUMAN CELL; IC 50; NONHUMAN; NUCLEOTIDE SEQUENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AZA COMPOUNDS; CARDIOVASCULAR AGENTS; CELL LINE; DELAYED RECTIFIER POTASSIUM CHANNELS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; ETHER-A-GO-GO POTASSIUM CHANNELS; GUINEA PIGS; HUMANS; INHIBITORY CONCENTRATION 50; LONG QT SYNDROME; QUINOLINES; RAZOXANE;

EID: 74549137240     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00371.x     Document Type: Article

References (32)

1. Kr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97 : 175 187.
2. + channel blockade by the fluoroquinolone antibiotic moxifloxacin. Br J Pharmacol 147 : 905 916.
3. Ks cardiac potassium current. Nature 384 : 78 80.
4. Bazett HC (1920). An analysis of the time-relations of electrocardiograms. Heart 7 : 353 370.
5. Carter SK, Blum RH (1974). New Chemotherapeutic agents... Bleomycin and Adriamycin. CA Cancer J Clin 24 : 322 331.
6. Chen X, Cass JD, Bradley JA, Dahm CM, Sun Z, Kadyszewski E et al. (2005). QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br J Pharmacol 146 : 792 799.
7. + current in heart: molecular basis, functional diversity, and contribution to repolarization. Acta Pharmacol Sin 25 : 137 145.
8. Dale KM, Lertsburapa K, Kluger J, White CM (2007). Moxifloxacin and torsade de pointes. Ann Pharmacother 41 : 336 340.
9. Demolis JL, Kubitza D, Tennezé L, Funck-Brentano C (2000). Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 68 : 658 666.
10. Fridericia LS (1920). Die Systolendauer im Elektrokardiogramm beinormalen Menschen and bei Herzkranken. Acta Medica Scandinavica 57 : 469 486.
11. Galetta F, Franzoni F, Cervetti G, Cecconi N, Carpi A, Petrini M et al. (2005). Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed Pharmacother 59 : 541 544.
12. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ (1981). Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391 : 85 100.
13. Hasinoff BB, Schroeder PE, Patel D (2003). The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Mol Pharmacol 64 : 670 678.
14. Imondi AR, Torre PD, Mazué G, Sullivan TM, Robbins TL, Hagerman LM et al. (1996). Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs. Cancer Res 56 : 4200 4204.
15. Ks in human ventricular muscle. Circulation 112 : 1392 1399.
16. Ks) and the repolarization reserve. Ann Noninvasive Electrocardiol 12 : 64 78.
17. + channel HERG. Mol Pharmacol 59 : 122 126.
18. Lacasse Y, Bolduc P (1992). Sudden death in leukemic patient treated with doxorubicin. Can J Cardiol 8 : 53 56.
19. + current in human ventricular myocytes. Circ Res 78 : 689 696. (Pubitemid 26106881)
20. Lu HR, Vlaminckx E, Van de Water A, Rohrbacher J, Hermans A, Gallacher DJ (2007). Corrigendum to 'In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.' Eur J Pharmacol 577 : 222 232.
21. Kr blockers. Basic Res Cardiol 102 : 42 51.
22. Nousiainen T, Vanninen E, Rantala A, Jantunen E, Hartikainen J (1999). QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. J Intern Med 245 : 359 364.
23. Saltiel E, McGuire W (1983). Doxorubicin (Adriamycin) cardiomyopathy. West J Med 139 : 332 341.
24. Ks potassium channel. Nature 384 : 80 83.
25. Ks by HMR 1556 increases the reverse rate-dependence of refractoriness prolongation by dofetilide in isolated rabbit ventricles. Br J Pharmacol 148 : 255 263.
26. Stark G, Stark U, Samonigg H, Kasparek K, Lueger A, Nagl S et al. (1990). Comparison of acute effects of anthracyclines on cardiac electrophysiological parameters of isolated guinea-pig hearts. Cancer Chemother Pharmacol 26 : 415 418.
27. Steinberg JS, Cohen AJ, Wasserman AG, Cohen P, Ross AM (1987). Acute arrhythmogenicity of doxorubicin administration. Cancer 60 : 1213 1218.
28. Wang GX, Wang YX, Zhou XB, Korth M (2001). Effects of doxorubicinol on excitation-contraction coupling in guinea pig ventricular myocytes. Eur J Pharmacol 423 : 99 107.
29. Wang YX, Korth M (1995). Effects of doxorubicin on excitation- concentration coupling in guinea pig ventricular myocardium. Circ Res 76 : 645 653.
30. Wiseman LR, Spencer CM (1998). Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs 56 : 385 403.
31. Wisialowski T, Crimin K, Engtrakul J, O'Donnell J, Fermini B, Fossa AA (2006). Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. J Pharmacol Exp Ther 318 : 352 359.
32. Yeh ETH, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C et al. (2004). Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109 : 3122 3131.